Haisco Pharmaceutical Group (002653.SZ) has received approval for the clinical trial of its innovative drug HSK60002 tablets.

Haisco Pharmaceutical Group (002653.SZ) announced that it has recently received a "Clinical Trial Approval Notice" issued by the National Medical Products Administration. After review, it was determined that HSK60002 tablets, accepted for review in July 2026, meet the relevant requirements for drug registration, and permission is granted to proceed with clinical trials. HSK60002 tablets are an independent intellectual property oral small molecule formulation developed by the company, intended for the treatment of inflammatory diseases. Preclinical research data indicates that HSK60002 demonstrates significant pharmacological activity in relevant animal models, with a clear mechanism of action. Based on the existing results, HSK60002 presents a distinct development value and favorable prospects for translation, promising to provide clinical patients with a new, efficient, and safe treatment option.